Amanda Hanson

Amanda Hanson (1985 – January 25, 2024) was an American journalist and television presenter. Provided by Wikipedia
Showing 1 - 5 results of 5 for search 'Amanda Hanson', query time: 0.03s Refine Results
  1. 1
    The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)

    The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD) by Amanda Hanson, Danielle Wilhelmsen, Johanna K. DiStefano

    Published 2018-08-01
    Get full text
    Article
  2. 2
    Interleukins 7 and 15 Maintain Human T Cell Proliferative Capacity through STAT5 Signaling.

    Interleukins 7 and 15 Maintain Human T Cell Proliferative Capacity through STAT5 Signaling. by Adam Drake, Mandeep Kaur, Bettina P Iliopoulou, Ryan Phennicie, Amanda Hanson, Jianzhu Chen

    Published 2016-01-01
    Get full text
    Article
  3. 3
    AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p.

    AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p. by Glenn S Gerhard, Amanda Hanson, Danielle Wilhelmsen, Ignazio S Piras, Christopher D Still, Xin Chu, Anthony T Petrick, Johanna K DiStefano

    Published 2019-01-01
    Get full text
    Article
  4. 4
    Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis

    Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis by Glenn S. Gerhard, Bethany Davis, Xiumei Wu, Amanda Hanson, Danielle Wilhelmsen, Ignazio S. Piras, Christopher D. Still, Xin Chu, Anthony T. Petrick, Johanna K. DiStefano

    Published 2020-07-01
    Get full text
    Article
  5. 5
    ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.

    ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. by Amanda Hanson, Kutlu Elpek, Ellen Duong, Lindsey Shallberg, Martin Fan, Calvin Johnson, Matthew Wallace, George R Mabry, Stephen Sazinsky, Lauren Pepper, Chengyi J Shu, Sriram Sathyanarayanan, Sarah Zuerndorfer, Tyler Simpson, Monica Gostissa, Michael Briskin, Deborah Law, Jennifer Michaelson, Christopher J Harvey

    Published 2020-01-01
    Get full text
    Article

Search Tools: